Ali Greatsinger
Education
M.P.H., social and behavioral sciences, Harvard T. H. Chan School of Public Health; B.A., biological sciences, The University of Chicago
Summary of Experience
Ms. Greatsinger is an experienced epidemiology and health outcomes researcher, with a particular focus on real-world data assessments and patient outcomes research. Her research applies a wide range of methodologies, including retrospective claims analyses, electronic medical records analyses, chart reviews, surveys, economic modeling, and clinical trial data analyses. Ms. Greatsinger has extensive experience designing and implementing advanced data analytics to support a range of disease areas, including oncology, nephrology, infectious diseases, and autoimmune diseases. Her research has been published in peer-reviewed journals, including the Journal of the American Heart Association and the Journal of the Academy of Nutrition and Dietetics, and presented at clinical and economic conferences.
-
Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real-World Evidence Study
International Journal of Urology, 2025
2025Morgans AK, Mucha L, Quicquaro C, Shih V, Xie B, Young C, Yang H, Liu Q, Greatsinger A, Lax A
-
Sodium Zirconium Cyclosilicate Duration and Hyperkalemia-Related Healthcare Encounters in Patients with Heart Failure and Cardio/Renal Dysfunction: The GALVANIZE Outcome Study
Drugs - Real World Outcomes, 2025
2025Agiro A, Mu F, Cook EE, Greatsinger A, Chen J, Sundar M, Zhao A, Colman E, Malhotra A
-
Psychometric evaluation of novel hyperphagia questionnaires in a real-world setting for patients with a rare MC4R pathway disease
Orphanet Journal of Rare Diseases, 2025
2025Pomeroy J, Mallya UG, Yang M, Huber C, Greatsinger A, Hagopian E, Haqq AM
-
Renin-Angiotensin-Aldosterone System Inhibitor Dosing After Initiation of Outpatient Sodium Zirconium Cyclosilicate Therapy: The GALVANIZE RAASi Real-World Evidence Study
Advances in Therapy, 2025
2025Agiro A, Greatsinger A, Mu F, Cook EE, Chen J, Sundar M, Zhao A, Colman E, Malhotra A
-
Hyperkalemia and the Risks of Adverse Cardiovascular Outcomes in Patients With Chronic Kidney Disease
Journal of the American Heart Association, 2025
2025Agiro A, Mu F, Cook E, Greatsinger A, Chen J, Zhao A, Louden E, Colman E, Desai P, Chertow GM
-
Hyperkalemia and Risk of Chronic Kidney Disease Progression: A Propensity Score Matched Analysis
Kidney360, 2024
2024Agiro A, Cook E, Mu F, Greatsinger A, Chen J, Zhao A, Louden E, Colman E, Desa P, Chertow GM
-
Frequency and economic burden of exacerbations in inhaled corticosteroid/long-acting beta-agonist-treated patients with asthma: A retrospective US claims study
Respiratory Medicine, 2024
2024Duh MS, Roberts MH, Rothnie KJ, Cheng WY, Thompson-Leduc P, Zhang S, Czira A, Slade D, Greatsinger A, Zhang A, Mapel D
-
Development and validation of a claims-based algorithm to identify moderate exacerbations in patients with asthma treated in the US
Respiratory Medicine, 2024
2024Roberts MH, Duh MS, Rothnie KJ, Zhang S, Czira A, Slade D, Cheng WY, Thompson-Leduc P, Greatsinger A, Zhang A, Mapel D
-
Real-world survival and economic burden among patients with locally advanced or metastatic urothelial carcinoma in the United States
Urologic Oncology, 2024
2024Chen RC, Fuldeore R, Greatsinger A, Hepp Z, Liu Q, Wright P, Xie B, Yang H, Young C, Zhang A, Mucha L
-
Real-world survival and economic burden among patients with locally advanced or metastatic urothelial carcinoma in the United States
Urologic Oncology, 2024
2024Chen RC, Fuldeore R, Greatsinger A, Hepp Z, Liu Q, Wright P, Xie B, Yang H, Young C, Zhang A, Mucha L
-
Economic burden of recurrent hyperkalemia in patients with chronic kidney disease
Journal of Managed Care & Specialty Pharmacy, 2024
2024Bakris G, Agiro A, Greatsinger A, Mu F, Cook EE, Sundar M, Louden E, Colman E, Desai P
-
Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer
Prostate Cancer and Prostatic Diseases, 2024
2024George DJ, Ramaswamy K, Yang H, Liu Q, Zhang A, Greatsinger A, Ivanova J, Thompson B, Emir B, Hong A, Freedland SJ
-
Unintended Consequences of Increased Out-of-Pocket Costs During Medicare Coverage Gap on Anticoagulant Discontinuation and Stroke
Advances in Therapy, 2023
2023Salam T, Desai U, Lefebvre P, Jian-Yu E, Greatsinger A, Zacharia N, Laliberté F, Bookhart B, Kharat A
-
Burden of Hyperphagia and Obesity in Bardet-Biedl Syndrome: A Multicountry Survey
Orphanet Journal of Rare Diseases, 2023
2023Forsythe E, Mallya UG, Yang M, Huber C, Cala ML, Greatsinger A, Hagopian E, Pomeroy J, Haqq AM
-
Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States
Advances in Therapy, 2023
2023Zhang S, Bensimon AG, Xu R, Jiang R, Greatsinger A, Zhang A, Fukunaga-Kalabis M, Krepler C
-
Caregiver Burden in Bardet-Biedl Syndrome: Findings from the CARE-BBS Study
Orphanet Journal of Rare Diseases, 2023
2023Forsythe E, Mallya UG, Yang M, Huber C, Cala ML, Greatsinger A, Hagopian E, Pomeroy J, Haqq AM
-
Long-term treatment effects of inotersen on health-related quality of life in patients with hATTR amyloidosis with polyneuropathy: Analysis of the open-label extension of the NEURO-TTR trial
Muscle & Nerve, 2022
2022Karam C, Brown D, Yang M, Done N, Zhu JJ, Greatsinger A, Bozas A, Vera-Llonch M, Signorovitch J
-
Real-World Economic Burden Among Patients With And Without Heart Failure Worsening After Cardiac Resynchronization Therapy
Advances in Therapy, 2021
2021Chung ES, Rickard J, Lu X, DerSarkissian M, Zichlin ML, Cheung HC, Swartz N, Greatsinger A, Duh MS
-
July 16, 2025
-
December 4, 2024
-
September 11, 2024
-
December 1, 2023
-
October 23, 2023